PEG3350

DRUG3 trials

Sponsors

Braintree Laboratories, Istituto Clinico Humanitas, John Lenehan

Conditions

Colon AdenomaColon LesionColon PolypConstipationUnresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

RecruitingNCT06393400

John LenehanUnresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma

Start: 2025-01-08End: 2028-02-29Target: 20Updated: 2025-01-23

Phase 4

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

CompletedNCT00583609

Braintree LaboratoriesConstipation

Start: 2007-09-30End: 2008-07-31Target: 20Updated: 2009-09-28

Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

CompletedNCT03742232

Istituto Clinico HumanitasColon Adenoma, Colon Lesion, Colon Polyp

Start: 2018-10-31End: 2020-03-31Updated: 2020-08-27

Related Papers

Fecal microbiota transplantation (FMT) combined with first-line gemcitabine and nab-paclitaxel chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-01-10

Novel 1-L polyethylene glycol + ascorbate versus high-volume polyethylene glycol regimen for colonoscopy cleansing: a multicenter, randomized, phase IV study.

2021-04-3015 citations

RANDOMIZED CONTROLLED TRIAL COMPARING THE BOWEL CLEANSING EFFICACY OF NOVEL 1 LITRE POLYETHYLENE GLYCOL+ASCORBATE NER1006 VERSUS HIGH-VOLUME POLYETHYLENE GLYCOL USING A SPLIT DOSING REGIMEN

Endoscopy2020-04-01